Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

GlaxoSmithKline Pharmaceuticals Limited's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 2.027000
forwardPE 30.617922
debtToEquity 1.467000
earningsGrowth 0.057000
revenueGrowth 0.021000
grossMargins 0.640050
operatingMargins 0.344190
trailingEps 61.220000
forwardEps 77.275000

GLAXO's current ratio is 2.027, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as GLAXO should not face any issues meeting its short-term liabilities with available resources.
GlaxoSmithKline Pharmaceuticals Limited's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
GLAXO's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for GLAXO's financial performance.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

GLAXO's present price, in relation to its projections, shows no obvious risks or opportunities. This neutral outlook suggests stability, where investors might consider waiting for more decisive signals before making any significant moves.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


The recent buy bias from analysts suggests GlaxoSmithKline Pharmaceuticals Limited is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, GlaxoSmithKline Pharmaceuticals Limited appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.